KM Biologics Co. Ltd. Enters Into A Technology Collaboration With Serum Institute Of India

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) hereby announces that KM Biologics Co., Ltd., a group company of Meiji Seika Pharma, has entered into a technology collaboration with Serum Institute of India Private Limited (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer, for the development and manufacturing of a Japanese encephalitis vaccine, and has achieved the first milestone under this collaboration.

This collaboration has been carried out based on a technology transfer agreement between KM Biologics and SII for the development and manufacturing of a Japanese encephalitis vaccine. With the achievement of this milestone, SII will initiate development activities in India for the Japanese encephalitis vaccine currently manufactured and marketed by KM Biologics. Going forward, the two companies will work closely together to advance development and to establish anufacturing and supply by SII.

Japanese encephalitis remains a significant public health challenge, particularly in Asia, and continues to be a major infectious disease concern. In India, there is a strong demand for a stable and large-scale supply of vaccines under the national immunization program. Leveraging the expertise in vaccine research, development, manufacturing, and quality control that they have cultivated over the years, Meiji Seika Pharma and KM Biologics have positioned contributing to global infectious disease control as a key mission. Through collaboration with SII, which possesses one of the world's largest vaccine manufacturing capacities, the establishment of a stable supply for Japanese encephalitis vaccines in India and contributions to public health are expected.

Meiji Seika Pharma is advancing its business expansion primarily in regions across the Global South. This collaboration with SII will serve as an important foundation for future business development, and by maximizing its strong sales channels, particularly in Asia, the company will continue to contribute to the improvement of global public health.

About Serum Institute of India Private Limited (SIIPL)
Serum Institute of India Pvt. Ltd., is a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. Present across 170+ countries, including the US, UK, and Europe, SII holds the distinction of being the world’s largest vaccine manufacturer. SII’s multifunctional production and one-of-the-largest facility in Manjri and Hadapsar Pune, with an annual capacity of 4 billion doses, has saved over 30 million lives over the years.

Founded in 1966, SII’s primary mission is to produce life-saving immunobiological drugs, with a particular emphasis on affordability and accessibility. Guided by a strong commitment to improving global health, the company has played a pivotal role in reducing the prices of essential vaccines, such as Polio, Rabies, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, they are the manufacturers of ‘Pneumosil,’ the world’s most affordable PCV, and the first indigenous qHPV vaccine in India. Moreover, SII has been at the forefront of the global fight against COVID-19, delivering over 2 billion doses of the COVID-19 vaccine worldwide.

To further expand its global presence and ensure widespread vaccine availability, SII has established Serum Life Sciences Ltd, a subsidiary in the UK. Through relentless pursuit of innovation, SII continues to champion the cause of affordable vaccines, making a positive impact on the lives of millions worldwide. For more information, visit www.seruminstitute.com.